nirmatrelvir 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antivirals 5520 2628280-40-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • nirmatrelvir
  • paxlovid
  • PF-07321332
Nirmatrelvir plus ritonavir (Paxlovid) is an antiviral therapeutic developed by Pfizer for the treatment and post-exposure prophylaxis of coronavirus disease 2019 (COVID-19). It received conditional approval by EMA, FDA and PMDA. Nirmatrelvir (PF-07321332) is a peptidomimetic inhibitor of the SARS-CoV-2 main protease (Mpro), also referred to as 3C-like protease (3CLpro) or nsp5 protease. Inhibition of the SARS-CoV-2 Mpro renders the protein incapable of processing polyprotein precursors which leads to the prevention of viral replication. Ritonavir inhibits the CYP3A-mediated metabolism of PF-07321332, thereby providing increased plasma concentrations of PF-07321332.
  • Molecular weight: 499.54
  • Formula: C23H32F3N5O4
  • CLOGP: 1.83
  • LIPINSKI: 0
  • HAC: 9
  • HDO: 3
  • TPSA: 131.40
  • ALOGS: -4.26
  • ROTB: 8
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.60 g O

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Jan. 28, 2022 EMA Pfizer Europe MA EEIG
May 25, 2023 FDA Pfizer, Inc.
Feb. 10, 2022 PMDA PFIZER JAPAN INC

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug interaction 72.55 61.08 26 80 225920 34730905

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug interaction 129.31 89.17 45 161 415138 79329044
Acute kidney injury 90.37 89.17 37 169 519367 79224815

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J05AE30 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Protease inhibitors
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000998 Antiviral Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D011480 Protease Inhibitors
MeSH PA D000084762 Viral Protease Inhibitors
CHEBI has role CHEBI:147285 SARS coronavirus main protease inhibitors
CHEBI has role CHEBI:149553 anticoronaviral drug
CHEBI has role CHEBI:35660 HIV protease inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
COVID-19 indication 840539006




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
150MG;100MG PAXLOVID (COPACKAGED) PFIZER N217188 May 25, 2023 RX TABLET ORAL 11351149 Aug. 5, 2041 TREATMENT OF MILD-TO-MODERATE CORONAVIRUS DISEASE 2019 (COVID-19) IN ADULTS WHO ARE AT HIGH RISK FOR PROGRESSION TO SEVERE COVID-19, INCLUDING HOSPITALIZATION OR DEATH
150MG;100MG PAXLOVID (COPACKAGED) PFIZER N217188 May 25, 2023 RX TABLET ORAL 11541034 Oct. 31, 2041 TREATMENT OF MILD-TO-MODERATE CORONAVIRUS DISEASE 2019 (COVID-19) IN ADULTS WHO ARE AT HIGH RISK FOR PROGRESSION TO SEVERE COVID-19, INCLUDING HOSPITALIZATION OR DEATH

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
150MG;100MG PAXLOVID (COPACKAGED) PFIZER N217188 May 25, 2023 RX TABLET ORAL May 25, 2028 NEW CHEMICAL ENTITY
300MG;100MG PAXLOVID (COPACKAGED) PFIZER N217188 May 25, 2023 RX TABLET ORAL May 25, 2028 NEW CHEMICAL ENTITY

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Replicase polyprotein 1ab Enzyme INHIBITOR Ki 8.51 SCIENTIFIC LITERATURE DRUG LABEL

External reference:

IDSource
CHEBI:170007 CHEBI
ZGW PDB_CHEM_ID
CHEMBL4802135 ChEMBL_ID
C000718217 MESH_SUPPLEMENTAL_RECORD_UI
C000719967 MESH_SUPPLEMENTAL_RECORD_UI
11503 IUPHAR_LIGAND_ID
DB16691 DRUGBANK_ID
018919 NDDF
4041063 VANDF
C5545149 UMLSCUI
D12244 KEGG_DRUG
12161 INN_ID
155903259 PUBCHEM_CID
2587892 RXNORM
354383 MMSL
40180 MMSL
d09839 MMSL
7R9A5P7H32 UNII

Pharmaceutical products:

None